Search companies

Live

VITRAFY LIFE SCIENCES LIMITED (ASX: VFY)

Health care · News and insights

VFY: $2.65 +3.92% · MC: $165M

Latest VFY announcements

Announcement Insights

Vitrafy Expands US Partnerships as It Funds Device Scale-Up and Cell-Therapy Push

Vitrafy is broadening its US commercial reach while directing capital toward manufacturing and device scale-up. In October, it added Versiti as its third US civilian blood partner and agreed to work with Charter Medical in cell and gene therapy, with partnerships covering about 17% of US civilian blood collection sites; device deployments were planned for the quarter and US medical device listing remained on track for late 2026. At the November AGM, shareholders approved a 10% placement facility as the company pursued growth over FY27 and beyond, with about A$38 million in cash and term deposits at September-end.

Updated 17 Nov 2026, 03:49 PM Sydney time
Share
Sources2026 Annual General Meeting Addresses & PresentationResults of 2026 Annual General MeetingRelease of Securities from Mandatory EscrowQ1 FY27 Quarterly Activities Report and Appendix 4CQuarterly Investor Briefing Presentation
Comments

Vitrafy Targets US Health Market as Shareholders Back Placement Facility

2026-11-17 · Health care

VFY: $2.65 +3.92% · MC: $165M

Vitrafy Life Sciences is focusing its direct commercial efforts on US human health while pursuing animal reproduction through its partnership with IMV Technologies. The company expects short-term costs to rise as it invests in validation, manufacturing and delivery of initial medical devices, and held approximately $38 million in cash and term deposits at the end of September. At its annual meeting, shareholders approved an additional placement facility and performance rights for CEO Brent Owens, and elected Jeannette Joughin and re-elected Kate Munnings as directors.

Updated 2026-11-17 16:14
Share
Sources2026 Annual General Meeting Addresses & PresentationResults of 2026 Annual General Meeting
Comments

Vitrafy Flags Release Of 14 Million Shares From Escrow

2026-11-09 · Health care

VFY: $2.34 -4.49% · MC: $165M

Vitrafy Life Sciences says approximately 14 million ordinary shares and options will be released from mandatory escrow on 26 November, including the shares it plans to apply to have quoted after the escrow period. The release also covers options expiring in 2027 and 2029.

Updated 2026-11-09 12:48
Share
SourcesRelease of Securities from Mandatory Escrow
Comments

Vitrafy expands US blood partnerships and enters cell therapy market

2026-10-28 · Health care

VFY: $2.36 -2.07% · MC: $165M

Vitrafy added Versiti as its third US civilian blood partner and agreed to work with Charter Medical, extending its cryopreservation program into cell and gene therapy. Its partnerships now cover approximately 17% of US civilian blood collection sites, while partner device deployments are planned for the current quarter and US medical device listing remains on track for late 2026. The company ended the quarter with A$38 million in cash and term deposits.

Updated 2026-10-28 08:19
Share
SourcesQ1 FY27 Quarterly Activities Report and Appendix 4CQuarterly Investor Briefing Presentation
Comments